The article highlights five small-cap stocks offering high dividend yields (6.6%-11%) that remain undervalued despite strong 2026 performance. The author recommends regional banks and energy companies as income-generating opportunities, though warns of risks including economic sensitivity and potential dividend sustainability concerns.

Good Start® | Dr. Brown's™ infant formula has been named 'Baby Food Product of the Year' at the 2025 Baby Innovation Awards. The partnership combines Good Start's 50+ year heritage with Dr. Brown's pediatrician-recommended bottles to offer tolerance-focused infant formulas including Soothe Pro®, Gentle Pro®, and Soy-ease Pro® variants designed to address common feeding challenges like fussiness, gas, and digestive issues.

The global scar treatment market is projected to grow from USD 26.60 billion in 2025 to USD 56.30 billion by 2033, with a CAGR of 9.91%. Growth is driven by increasing awareness of advanced cosmetic and reconstructive procedures, rising prevalence of acne, surgical, and traumatic scars, and technological advancements in minimally invasive treatments. The U.S. market alone is expected to reach USD 17.69 billion by 2033.

The article examines three high-yielding healthcare stocks: Perrigo (8.2% yield) is cautioned as a potential value trap despite strong dividend history; Pfizer (6.7% yield) is viewed more favorably with post-COVID catalysts and GLP-1 product launches; Embecta (5.5% yield) shows turnaround potential as it pivots toward the GLP-1 pen needle business.

The global infant nutrition market is shifting from volume-based to value-driven growth, projected to reach $162.08 billion by 2035 at a 10.26% CAGR. Despite declining birth rates, premium formulations and specialized nutrition products are driving growth. Major players are investing heavily in domestic manufacturing, regulatory compliance, and product innovation, while safety recalls and consolidation reshape the competitive landscape.

Perrigo Company PLC is highlighting National Store Brand Month, emphasizing how store brand over-the-counter (OTC) health and self-care products offer consumers 25%-30% retail price savings compared to national name brands while maintaining the same active ingredients and FDA standards. The company encourages consumers to stock up on essential OTC products like pain relievers, cough suppressants, and decongestants as cold and flu season peaks.

A class action lawsuit has been filed against Perrigo Company plc alleging that the company made materially false statements and failed to disclose significant issues with its infant formula business acquired from Nestlé, including underinvestment, manufacturing deficiencies, and overstated financial results. Investors who purchased Perrigo securities between February 27, 2025 and November 4, 2025 are encouraged to join the case.

A class action securities lawsuit has been filed against Perrigo Company plc for alleged securities fraud between February 27, 2023 and November 4, 2025. The complaint alleges that the company made false statements regarding its infant formula business acquired from Nestlé, concealing significant underinvestment, manufacturing deficiencies, and the need for substantial capital expenditures, which resulted in overstated financial results.

A class action lawsuit has been filed against Perrigo Company plc for allegedly failing to disclose significant underinvestment, manufacturing deficiencies, and substantial remediation costs in its infant formula business acquired from Nestlé. The company announced disappointing Q3 2025 results and a strategic review of the business on November 5, 2025, causing the stock to plunge 25.2%. Investors who purchased shares between February 27, 2023 and November 4, 2025 have until January 16, 2026 to apply as lead plaintiff.

Law Offices of Howard G. Smith has announced securities fraud class action lawsuits against three publicly-traded companies: Perrigo Company plc (PRGO) for allegedly overstating financial results related to its Nestlé infant formula acquisition; Jayud Global Logistics Limited (JYD) for involvement in a fraudulent stock promotion scheme with coordinated share dumping; and StubHub Holdings, Inc. (STUB) for allegedly misleading statements about free cash flow impacts from vendor payment timing changes. Investors have until mid-to-late January 2026 to file lead plaintiff motions.

Levi & Korsinsky, LLP has filed class action securities lawsuits against Perrigo Company plc for alleged securities fraud between February 2023 and November 2025. The complaint alleges that Perrigo made false statements regarding its infant formula business acquired from Nestlé, concealing significant underinvestment, manufacturing deficiencies, and the need for substantial capital expenditures, which resulted in overstated financial results. Investors who suffered losses have until January 16, 2026 to request lead plaintiff status.

A class action lawsuit has been filed against Perrigo Company plc for alleged securities fraud. The complaint alleges that Perrigo made materially false statements and failed to disclose significant underinvestment and manufacturing deficiencies in its infant formula business acquired from Nestlé, resulting in overstated financial results. Investors who purchased Perrigo securities between February 27, 2025 and November 4, 2025 are encouraged to join the case, with a lead plaintiff deadline of January 16, 2026.